Home › Alzheimer's Disease › NCT07222280
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
Who can join
Ages 60 to 90 · All sexes
Full eligibility criteria
Inclusion Criteria: * Ages 60 to 90 years old * No prior diagnosis of dementia * Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state Exclusion Criteria: * Age under 60 years * Prior diagnosis of dementing illness or other organic etiology to cognitive impairment
About the study
The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease.
* Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
What is being tested
- Quest AD-Detect blood test (diagnostic test)
Sponsor: Covenant Health, US · Participants: 30 · Started: Jun 10, 2025
Contact the study team
- Clinical Research Nurse Coordinator · Phone: 865-331-1337
Official record on ClinicalTrials.gov — NCT07222280
Locations in the U.S.
| Tennessee | Cumberland Medical Center, Crossville Roane Medical Center, Harriman Fort Sanders Regional Medical Center, Knoxville Fort Loudon Medical Center, Lenoir City Methodist Medical Center, Oak Ridge LeConte Medical Center, Sevierville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.